Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, May 1, 2024— IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $964 million for the first quarter of 2024, an increase of 7% as reported and organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and or ...

Analysts on Wall Street project that Idexx Laboratories (IDXX) will announce quarterly earnings of $2.68 per share in its forthcoming report, representing an increase of 5.1% year over year. Revenues are projected to reach $966.4 million, increasing 7.4% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company an ...

Investors looking for stocks in the Medical - Instruments sector might want to consider either Thermo Fisher Scientific (TMO) or Idexx Laboratories (IDXX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank i ...

In the latest market close, Idexx Laboratories (IDXX) reached $519.81, with a +0.99% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.15% for the day. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.32%.Shares of the Animal diagnostic and health care company have depreciated by 6.13% over the course of the past month, underperforming the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65%.T ...

Idexx Laboratories (IDXX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Idexx Laboratories (IDXX) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.When looking at the last two reports, this Animal diagnostic and health care company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 8.09%, on average, in the last two quarters. ...

Topic 1: Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the Asia-Pacific region [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8%, primarily due to increased marketing and R&D investments [3]. Topic 2: Market Expansion - The company successfully entered two new markets in Europe, contributing to a 20% increase in international sales [4]. - A new distribution center was opened in South America to support regional growth [1]. - Strategic partnerships were formed with local retailers in Southeast Asia to enhance market penetration [3]. Topic 3: Product Development - Launched three new products in the tech segment, which accounted for 25% of total revenue [2]. - R&D investment increased by 10% to accelerate innovation and product differentiation [4]. - Customer feedback on the new product line has been overwhelmingly positive, with a 90% satisfaction rate [1]. Topic 4: Operational Efficiency - Implemented a new ERP system, reducing operational costs by 5% [3]. - Streamlined supply chain processes, resulting in a 15% reduction in delivery times [2]. - Employee training programs were expanded, leading to a 10% increase in productivity [4]. Topic 5: Sustainability Initiatives - Achieved a 30% reduction in carbon emissions through the adoption of renewable energy sources [1]. - Launched a recycling program that has successfully recycled 50% of manufacturing waste [3]. - Committed to achieving net-zero emissions by 2030, with interim targets set for 2025 [2]. Topic 6: Corporate Governance - Appointed two new independent directors to the board, enhancing governance and oversight [4]. - Implemented a new whistleblower policy to ensure ethical practices across the organization [1]. - Conducted annual audits, resulting in a 100% compliance rate with regulatory requirements [3].

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the BofA Securities Animal Health Virtual Summit. Monday, March 4, 11:00 am – 11:30 am ...

IDEXX Laboratories, Inc. (IDXX) is likely to grow in the coming quarters, backed by the sustained success of CAG’s recurring diagnostic products and services. The company’s international business performance is gaining from its expanded global commercial capability. However, IDEXX’s operations are prone to macroeconomic challenges and foreign exchange fluctuations.In the past year, this Zacks Rank #3 (Hold) stock has increased 8.9% compared with the 3.7% rise of the industry and 22.1% growth of the S&P 500 ...

IDEXX Laboratories, Inc.’s (IDXX) strong global expansion and improved commercial capability aid growth. However, macroeconomic woes dent growth. The stock carries a Zacks Rank #3 (Hold).IDEXX’s Diagnostics business is one of the fastest-growing areas in the veterinary clinic space since the determination of a patient's health status and the best treatment path often require testing. IDEXX provides advanced diagnostic capabilities that meet veterinarians’ diverse needs through a variety of modalities, inclu ...